Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 171

Next Previous
X
Search
Drug Profile

AB 171

Alternative Names: AB171; LA 419

Latest Information Update: 03 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lacer
  • Developer Lacer; Oruka Therapeutics
  • Class Furans; Heart failure therapies; Organic nitrates; Small molecules; Sugar alcohols; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic heart failure; Peripheral arterial disorders
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 29 Aug 2024 ARCA biopharma Inc has merged with Oruka Therapeutics to form Oruka Therapeutics
  • 27 Jul 2022 Lacer has been acquired by Italfarmaco
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Chronic-heart-failure in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top